Inflammatory Diseases Explained in Artistic Designs
PTSM: Pharmaceutical Technology Sourcing and Management
AbbVie launches art initiative designed to explore impact of chronic inflammatory diseases.
AbbVie has launched 'Perspectives – Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases and their impact on patients and society. More than 100 artistic expressions from the initiative debuted at the 9th Congress of theEuropean Crohn's and Colitis Organization in Copenhagen, Denmark from Feb. 20-22.
The initiative involves more than 200 artists from 40 countries around the world. In addition to professional and independent artists, Perspectives included art studentsfrom more than 15 universities in France, Canada, Italy, and Spain through collaborations with the Polytechnic University of Valencia (Universitat Politecnica de Valencia).
The artistic expressions include, but are not limited to, sculptures, photographs, paintings, and installations. Perspectives will visit various art galleries and medical conferences throughout the world, with additional exhibition dates and locations to be announced.
Source: AbbVie
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
